PROCEPT BioRobotics Corpo... (PRCT)
NASDAQ: PRCT
· Real-Time Price · USD
39.15
0.69 (1.79%)
At close: Sep 23, 2025, 3:59 PM
39.39
0.61%
After-hours: Sep 23, 2025, 07:27 PM EDT
1.79% (1D)
Bid | 39.08 |
Market Cap | 2.18B |
Revenue (ttm) | 274.95M |
Net Income (ttm) | -84.14M |
EPS (ttm) | -1.54 |
PE Ratio (ttm) | -25.42 |
Forward PE | -39.24 |
Analyst | Buy |
Dividends | n/a |
Ask | 39.26 |
Volume | 1,093,869 |
Avg. Volume (20D) | 1,128,622 |
Open | 38.47 |
Previous Close | 38.46 |
Day's Range | 38.32 - 39.99 |
52-Week Range | 36.75 - 103.81 |
Beta | 1.02 |
Ex-Dividend Date | n/a |
About PRCT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PRCT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PRCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsPROCEPT BioRobotics Corporation is scheduled to release its earnings on
Oct 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-13.35%
PROCEPT BioRobotics shares are trading lower follo...
Unlock content with
Pro Subscription
1 month ago
-5.05%
PROCEPT BioRobotics shares are trading lower following the release of its Q2 financial results.

1 month ago · seekingalpha.com
Procept BioRobotics: Increasing Average Selling Price, Initiate At BuyProcept BioRobotics Corporation is in the early stages of penetrating a massive $20B BPH surgery market with its innovative, recurring-revenue robotic systems. The company's strong revenue and install...

1 month ago · seekingalpha.com
PROCEPT BioRobotics Corporation (PRCT) Q2 2025 Earnings Call TranscriptPROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Kevin Waters - Executive VP & CFO Larry L. Wood - Independent Director Ma...

1 month ago · fool.com
PROCEPT BioRobotics (PRCT) Earnings TranscriptImage source: The Motley Fool.